Paul

Thank you for posting that. MSKCC is highly regarded by OCF posters. Erbitux has been a hot button issue here (okay, I get all hot about it and make it an issue). This study sums up the reasons why my RO at a CCC now refuses to give Erbitux and instead uses Carboplatin or Cisplatin: his patients who he had given Erbitux have had more recurrences than those he treated with platinum chemo. Ironically, I asked my RO to treat me with this "miracle drug" based on all the glowing articles overstating the Bonner results (which really only showed that Erbitux works better than nothing at all for chemo) as well as the newspaper articles at the time about "mean" countries denying state insurance coverage for Erbitux.
As the article notes, the Clinical trial comparing Erbitux to Cisplatin will finally answer these questions, although my guess is that the trial may be discontinued once the preliminary results are in.
I was glad to see the sentence with footnote 16 about the analysis of the Spectrum trials showing that Erbitux did not play well with HPV when used to treat recurrence or metastasis, When I first posted that possibility, I got lots of pushback so a MSKCC article helps validate my concern.
This is one time I hope I am wrong as many OCF posters have relied upon Erbitux. Plus it's important not to overstate Erbitux's limitations, it does work, but has not been proven to work better or even as well as cisplatin and carboplatin. That's the information I wish I had known back in 2007.
Charm
.